Edwards Lifesciences (NYSE:EW) won FDA approval to market its Sapien transcatheter aortic valve implantation system to lower-risk patients, despite concerns about limited patient data on the long-term side effects of the device.
Q3
GE Healthcare’s Q3 profits tick up on flat sales
GE Healthcare (NYSE:GE) boosted profits by 2% on flat sales during the 3rd quarter, but investors on Wall Street shaved nearly 3% from its parent company’s share price after overall revenues missed The Street’s expectations.
GE Healthcare posted profits of $620 million on sales of $4.31 billion during the 3 months ended Sept. 30, for a bottom-line gain of 2.0% but a top-line dip of 0.6%, compared with the same period last year.
Baxter ticks up on Q3 results
Boston Scientific earnings: Writedown pushes BSX into Q3 red
Boston Scientific (NYSE:BSX) took a writedown for the 2nd consecutive quarter today, posting a 3rd-quarter loss and lowering its sales outlook for the rest of the year.
Still, excluding 1-time items, the Natick, Mass.-based medical device company managed to beat Wall Street’s expectations by a penny.
Stryker’s Q3 results dash Wall Street’s hopes
Stryker (NYSE:SYK) just missed Wall Street’s expectations with its 3rd-quarter earnings and reduced its forecast for 2012 and 2013 today, sending shares down a tad in after-hours trading.
The Kalamazoo, Mich.-based medical device company cited "weaker results from key countries outside the U.S." and softer sales for its capital equipment business.
St. Jude Medical slides on potential FDA warning, lowered outlook
St. Jude Medical‘s (NYSE:STJ) stock took a hit today after the medical device company said it might get a warning from the FDA over one of its California factories and lowered its outlook for the rest of the year.
Intuitive Surgical slides after hours on lower procedure volumes
Intuitive Surgical (NSDQ:ISRG) delivered another Street-beating quarter today, but investors, spooked by sliding procedure volumes, shaved more than 5% from its share price in after-hours trading.
Johnson & Johnson hits 52-week high on boosted earnings forecast | Wall Street Beat
Shares of Johnson & Johnson (NYSE:JNJ) surged to a 52-week high today after the healthcare conglomerate boosted its 2012 earnings forecast after reporting a solid, Street-beating quarter (and despite a nearly 18% bottom-line slide).
FLASH: Johnson & Johnson reports Q3 earnings slip 18%, boosts outlook
Johnson & Johnson (NYSE:JNJ) beat Wall Street’s earnings expectations and boosted its profit outlook for the rest of the year this morning before the market’s open.
The New Brunswick, N.J.-based healthcare giant posted profits of $2.63 billion, or $1.05 per diluted share, on sales of $17.05 billion during the 3 months ended Sept. 30.
Misonix gains 19% on swing to black | Wall Street Beat
Misonix (NSDQ:MSON) shares are up 19% today after the medical device company swung to black ink for its fiscal 4th quarter and full year.
Farmingdale, N.Y.-based Misonix posted profits of $366,000, or 5¢ per share, on sales of $1.7 million for the 12 months ended June 30 – for a 26.7% top-line gain that helped Misonix swing from a $3.5 million loss during its last fiscal year.
MassDevice.com +3 | CMS targets “unnecessary” med-tech, J&J withdraws appeal and re-opens PMA, Q&A with JoeDeVivo
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.